General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Miracor(SIGNIFICANT), TherOx(SIGNIFICANT), Neovasc(SIGNIFICANT), Valfix(SIGNIFICANT), Ancora(SIGNIFICANT), Robocath(SIGNIFICANT), HeartFlow(SIGNIFICANT), Ablative Solutions(SIGNIFICANT), Vectorious(SIGNIFICANT), Elucid Bioimaging(SIGNIFICANT), Occlutech(SIGNIFICANT), Impulse Dynamics(SIGNIFICANT), Abiomed(MODEST), Adona Medical(SIGNIFICANT), Millennia Biopharma(SIGNIFICANT), Cardiac Success(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Oxitope(SIGNIFICANT), Daiichi Sankyo(MODEST), Apollo Therapeutics(SIGNIFICANT), HighLife(SIGNIFICANT), Elixir(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: Orchestra Biomed(SIGNIFICANT), Ancora(SIGNIFICANT), Applied Therapeutics(SIGNIFICANT), Aria(SIGNIFICANT), Biostar family funds(SIGNIFICANT), Cagent(SIGNIFICANT), Cardiac Success(SIGNIFICANT), Spectrawave(SIGNIFICANT), Valfix(SIGNIFICANT), Xenter(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Abiomed(SIGNIFICANT), Abbott(SIGNIFICANT), Shockwave(SIGNIFICANT), Pulnovo(SIGNIFICANT), Phillips(NONE), Cardiovascular Systems Inc.(SIGNIFICANT), Biosense Webster(SIGNIFICANT), Bioventrix(SIGNIFICANT), V-wave(SIGNIFICANT) OTHER FINANCIAL BENEFIT: IQVIA(SIGNIFICANT), Vascular Dynamics(SIGNIFICANT)

View Full Disclosure